https://www.ibtomato.com/ExternalView.aspx?type=1&no=18459IB토마토ko2026-05-28T18:01:42+09:00(공시톺아보기)해외거래소 공시, 국내에도 알려야 하는 이유https://www.ibtomato.com/ExternalView.aspx?type=1&no=18457IB토마토ko2026-05-28T18:45:00+09:00(경제TOP아보기)월드컵 돈잔치, FIFA는 웃고 방송사는 본전 싸움https://www.ibtomato.com/ExternalView.aspx?type=1&no=18455IB토마토ko2026-05-28T17:08:16+09:00동원참치액, 출시 3년 만에 시장 점유율 1위https://www.ibtomato.com/ExternalView.aspx?type=1&no=18447IB토마토ko2026-05-28T15:44:24+09:00(크레딧시그널)롯데캐피탈, 이자마진 감소에도 순익은 개선https://www.ibtomato.com/ExternalView.aspx?type=1&no=18446IB토마토ko2026-05-28T10:51:03+09:00(Deal모니터)DB손해보험, '기본자본' 또 발행…K-ICS 방어 고삐https://www.ibtomato.com/ExternalView.aspx?type=1&no=18437IB토마토ko2026-05-27T17:47:14+09:00(유증레이다)디와이씨, 차입 대신 LIG 유증…방산 확장 승부수https://www.ibtomato.com/ExternalView.aspx?type=1&no=18436IB토마토ko2026-05-27T17:02:31+09:00(부고)이석원(신한자산운용 대표이사)씨 장모상https://www.ibtomato.com/ExternalView.aspx?type=1&no=18425IB토마토ko2026-05-27T17:00:59+09:00에코글로우, 4년 적자에도 신사옥 '쇼핑'…기업가치 훼손 우려https://www.ibtomato.com/ExternalView.aspx?type=1&no=18424IB토마토ko2026-05-27T16:56:15+09:00배민 '8조 몸값'의 역설…매출 급증에도 이익·현금은 후퇴https://www.ibtomato.com/ExternalView.aspx?type=1&no=18434IB토마토ko2026-05-27T14:48:59+09:00(크레딧시그널)메리츠증권, IB로 쌓은 이익…부동산 리스크 넘을까https://www.ibtomato.com/ExternalView.aspx?type=1&no=18435IB토마토ko2026-05-27T14:44:05+09:00포스코, 철강재가 미아방지 목걸이로…아동 안전망 넓힌다https://www.ibtomato.com/ExternalView.aspx?type=1&no=18431IB토마토ko2026-05-27T11:33:30+09:00KB국민은행 인니법인, 현지선 흑자·연결선 적자…부실채권이 관건https://www.ibtomato.com/ExternalView.aspx?type=1&no=18430IB토마토ko2026-05-27T11:27:18+09:00IPO 예심 문턱 높아지자…중소형 증권사 파이프라인 '휘청'https://www.ibtomato.com/ExternalView.aspx?type=1&no=18433IB토마토ko2026-05-27T11:21:52+09:00(Deal클립)한국투자증권, 2.5조 주문에 금리도 낮췄다…차환 청신호https://www.ibtomato.com/ExternalView.aspx?type=1&no=18429IB토마토ko2026-05-27T11:18:35+09:00포스코, 하청 7000명 직고용…세제 혜택으로 부담 낮추나https://www.ibtomato.com/ExternalView.aspx?type=1&no=18427IB토마토ko2026-05-27T10:57:07+09:00에이프로젠바이오, 제약 흑자에도…오송공장 '생산 0'에 적자 늪https://www.ibtomato.com/ExternalView.aspx?type=1&no=18428IB토마토ko2026-05-27T06:00:00+09:00(데스크칼럼)성과급 전쟁이 남긴 숙제https://www.ibtomato.com/ExternalView.aspx?type=1&no=18422IB토마토ko2026-05-26T17:58:50+09:00(데이터센터PF)③기술·자금력 따라 양극화…대형사만 남나https://www.ibtomato.com/ExternalView.aspx?type=1&no=18421IB토마토ko2026-05-26T17:48:44+09:00여전사 녹색채권, '그린 프리미엄' 실종…발행 유인 꺾였다https://www.ibtomato.com/ExternalView.aspx?type=1&no=18426IB토마토ko2026-05-26T17:45:49+09:00(IPO클립)피스피스스튜디오, '마르디' 통했다…공모가 밴드 상단 확정https://www.ibtomato.com/ExternalView.aspx?type=1&no=18416IB토마토ko2026-05-26T17:05:33+09:00SC제일은행, 유동성은 쌓았지만…외화 방어력·수익성 '엇박자'https://www.ibtomato.com/ExternalView.aspx?type=1&no=18412IB토마토ko2026-05-26T16:57:39+09:00DH오토리드, 외형 키웠지만…현금흐름·유동성은 역행https://www.ibtomato.com/ExternalView.aspx?type=1&no=18420IB토마토ko2026-05-26T16:27:34+09:00(IPO인사이트)레몬헬스케어, 의료AI 내세웠지만…부채비율 996%https://www.ibtomato.com/ExternalView.aspx?type=1&no=18417IB토마토ko2026-05-26T15:43:40+09:00(홈플러스 회생기로)②유암코 투입론의 딜레마…MBK에 특혜 되나https://www.ibtomato.com/ExternalView.aspx?type=1&no=18414IB토마토ko2026-05-26T15:33:19+09:00이연제약, 2900억 공장 부담에 우판권 분할까지…현금 확보 '비상'https://www.ibtomato.com/ExternalView.aspx?type=1&no=18418IB토마토ko2026-05-26T11:22:40+09:00(크레딧시그널)IBK기업은행, 중기대출 확대에도 신용도 '안정적'https://www.ibtomato.com/ExternalView.aspx?type=1&no=18415IB토마토ko2026-05-26T11:17:58+09:00LS일렉트릭, 장길수 연임에 커진 독립성 의문…구자균과 접점 '줄줄이' https://www.ibtomato.com/ExternalView.aspx?type=1&no=18409IB토마토ko2026-05-26T06:00:00+09:00(데이터센터PF)②AI 시대 새 먹거리라더니…전력·민원에 사업 표류